[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"persistent-spinal-pain-syndrome-type-2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:persistent-spinal-pain-syndrome-type-2":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,66,91,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100609188","open-and-closed-loop-dtm-scs-in-patients-with-psps-type-2-endless-study-100609188",false,"NCT07211308","Open and Closed Loop DTM SCS in Patients With PSPS Type 2: ENDLESS Study","Open and Closed Loop Differential Target Multiplexed Spinal Cord Stimulation in Patients With Persistent Spinal Pain Syndrome Type II: a European Multicenter Cohort Study (ENDLESS)","ENDLESS","Inclusion Criteria:\n\n* having chronic pain as a result of PSPS-T2 that exists for at least 6 months with at least moderate pain intensity (4 or higher measured on numeric rating scale (NRS) or 31mm or higher measured on visual analogue scale (VAS) for the dominant pain location.\n* being offered treatment with DTM SCS\n* being at least 18 years old\n\nExclusion Criteria:\n\n* Expected inability of patients to properly operate the SCS system\n* History of coagulation disorders, lupus erythematosus, diabetic neuropathy\n* Active malignancy\n* Addiction to drugs and\u002For alcohol (more than 5 units \u002Fday)\n* Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact perception of pain, compliance to intervention and\u002For ability to complete questionnaires, as determined by the investigator\n* Immune deficiency (e.g. HIV positive, immunosuppressiva)\n* Life expectancy \\\u003C 1 year\n* Local infection or other skin disorder at site of incision\n* Pregnancy\n* Other implanted active medical device","ALL",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of Persistent Spinal Pain Syndrome Type II (PSPS-T2). Identification of clinical effective parameters concerning frequency, pulse duration, amplitude and battery consumption\u002Frecharge frequency and safety evaluation.",[24,25,26],"Persistent Spinal Pain Syndrome Type 2","Failed Back Surgery Syndrome","Failed Neck Surgery Syndrome","NOT_YET_RECRUITING","2025-09-29",{"date":30,"type":31},"2025-10-07","ACTUAL",{"date":33,"type":20},"2025-10-01",{"date":35,"type":20},"2029-01-01",{"name":37,"class":38},"Universitair Ziekenhuis Brussel","OTHER",2,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100575688","neuronal-activation-accuracy-in-closed-loop-spinal-cord-stimulation-100575688","NCT06775535","Neuronal Activation Accuracy in Closed-loop Spinal Cord Stimulation","Assessment of Neuronal Activation Accuracy and Stimulation Sensation in Patients with Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy","NAA","Inclusion Criteria:\n\n* Subject is deemed a suitable candidate for SCS trial and permanent implant and has been routinely scheduled to undergo an SCS trial phase with the Evoke SCS System.\n* Subject has a minimum of pain intensity of 5\u002F10 on the numeric rating scale (NRS) at baseline\n* Subject is ≥ 18 years old.\n* Subject is not pregnant or nursing.\n* Subject is willing and capable of giving informed consent.\n\nExclusion Criteria:\n\n* Subject currently has an active implantable device including pacemakers, spinal cord stimulator or intrathecal drug delivery system.\n* Subject is incapable of understanding or responding to the study questionnaires.\n* Subject is incapable of understanding or operating the patient programmer handset.","18 Years",{"count":50,"type":20},12,"Observational, prospective, single-center to assess neuronal activation accuracy and stimulation sensation in patients with closed-loop spinal cord stimulation therapy.",[53,54,24],"Chronic Pain","Neuropathic Pain","RECRUITING","2025-01-09",{"date":58,"type":31},"2025-01-15",{"date":60,"type":31},"2023-08-02",{"date":62,"type":20},"2029-12",{"name":64,"class":38},"Karel Hanssens",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100471622","effects-of-active-versus-passive-recharge-burst-spinal-cord-stimulation-on-pain-experience-in-persistent-spinal-pain-syndrome-type-2-a-multicenter-randomized-trial-burst-rap-study-100471622","NCT05421273","Effects of Active Versus Passive Recharge Burst Spinal Cord Stimulation on Pain Experience in Persistent Spinal Pain Syndrome Type 2: a Multicenter Randomized Trial (BURST-RAP Study)","BURST-RAP","Inclusion Criteria:\n\n* Subjects between 18 and 70 years of age\n* At least moderate level of catastrophizing as measured with the Pain catastrophizing scale (PCS) of at least 20 at first visit of the pain clinic.\n* Chronic pain diagnoses as PSPS Type 2 of at least 6 months\n* Neurologic exam without marked motor deficit.\n* LBP and\u002For leg pain intensity should be 5 or higher measured with the 11-box NRS 0-10\n* Meets all the inclusion criteria for the implantation of a neurostimulation system as typically utilized in the study center. PM: depression is not an exclusion criteria\n* Subject has been screened by a multi-disciplinary panel including a psychologist and deemed suitable for implantation\n* Subject is able and willing to comply with the follow-up schedule and protocol\n* Subject is able to provide written informed consent\n\nExclusion Criteria:\n\n* Female subject of childbearing potential is pregnant\u002Fnursing or plans to become pregnant during the course of the study\n* Escalating or changing pain condition within the past month as evidenced by investigator examination\n* BMI ≥35\n* \"Subject has had injection therapy or radiofrequency treatment for their low back pain (LBP) or leg pain within the past 3 months\"\n* Subject currently has an active implantable device including ICD, pacemaker, spinal cord stimulator or intrathecal drug pump\n* Subject is unable to operate the device\n* Severe spinal column degeneration likely to cause technical problems with neuromodulation, to be assessed by the treating physician\n* Previous Neurostimulation therapy","70 Years",{"count":75,"type":20},96,"INTERVENTIONAL",[78],"NA","Spinal cord stimulation (SCS) has shown to be an effective treatment for patients with persistent spinal pain syndrome Type 2 (PSPS Type 2). The method used to deliver electrical charge in SCS is important. One such method is burst stimulation. Two variations of burst waveforms are currently in use: one that employs active recharge and one that uses passive recharge. It is still unknown if there are clinical differences between active recharge and passive recharge burst SCS. To date, no clinical studies have been performed that directly compared these two burst stimulation waveforms. The objective of this Randomized Clinical Trial (RCT) is to assess and compare effect of passive recharge burst SCS with active recharge burst SCS on pain relief and motivational-emotional facets of pain",[24,25],"2024-11-15",{"date":83,"type":31},"2024-11-19",{"date":85,"type":31},"2022-02-16",{"date":87,"type":20},"2026-06-30",{"name":89,"class":38},"Rijnstate Hospital",6,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100444483","differential-target-multiplexed-spinal-cord-stimulation-100444483","NCT05068011","Differential Target Multiplexed Spinal Cord Stimulation","Differential Target Multiplexed Spinal Cord Stimulation: a Multicenter Cohort Study","DETECT","Inclusion Criteria:\n\n* Patients with severe chronic pain (\\> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician\n* Age \\> 18 years\n* Patient has been informed of the study procedures and has given written informed consent\n* Patient willing to comply with study protocol including attending the study visits\n\nExclusion Criteria:\n\n* Expected inability of the patient to receive or properly operate the spinal cord stimulation system\n* History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew\n* Active malignancy\n* Addiction to drugs, alcohol (\\>5 units per day) and\u002For medication\n* Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and\u002For ability to evaluate treatment outcome as determined by investigator\n* Immune deficiency (e.g. HIV positive, immunosuppressive treatment)\n* Life expectancy \\\u003C 1 year\n* Local infection or any other skin disorder at site of incision\n* Pregnancy\n* Other implanted active medical device",{"count":100,"type":20},250,"Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle\u002Fsurgical leads versus percutaneous leads.",[25,24],[104],"differential target multiplexed spinal cord stimulation","2024-08-15",{"date":107,"type":31},"2024-08-16",{"date":109,"type":31},"2021-10-06",{"date":111,"type":20},"2026-08",{"name":113,"class":38},"Moens Maarten",14,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":76,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100505455","pain-medication-tapering-for-patients-with-persistent-spinal-pain-syndrome-type-2-treated-with-spinal-cord-stimulation-100505455","NCT05861609","Pain Medication Tapering for Patients With Persistent Spinal Pain Syndrome Type 2, Treated With Spinal Cord Stimulation.","PIANISSIMO","Inclusion Criteria:\n\n* Patients with PSPS T2, defined as patients suffering from neuropathic pain of radicular origin with pain in the lower back and\u002For leg(s), of an intensity of at least 4\u002F10 on the Numeric Rating Scale, for a period of at least 6 months after a minimum of one anatomically successful spinal surgery and being refractory to conservative treatment (according to Belgian reimbursement rules from January 1st, 2018)\n* Patients need to be scheduled for SCS to be eligible for participation in the study\n* Currently taking opioids\n* 18 years and older\n* Speaking and reading Dutch or French\n\nExclusion Criteria:\n\n* Being actively treated for cancer.\n* Having a life expectancy below 6 months.\n* Receiving intrathecal drug delivery.\n* Patients with contraindications for Clonidine (e.g., known hypotension which requires medication) or for Buprenorphine\u002FNaloxone (e.g., severe respiratory insufficiency, hepatic insufficiency).\n* Epilepsy treated by Pregabalin.\n* Currently using benzodiazepines at more than 40 mg diazepam-equivalents per day.",{"count":123,"type":20},195,[78],"The primary objective of the study is to examine whether there is a difference in disability after 12 months of Spinal Cord Stimulation (SCS) in patients with Persistent Spinal Pain Syndrome Type 2 (PSPS T2) after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation. The secondary objective of the study is to examine whether there is a difference after 12 months of SCS in PSPS T2 patients after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation on pain intensity, health-related quality of life, participation, domains affected by substance use, anxiety and depression, medication use, psychological constructs, sleep, central sensitization, and healthcare expenditure.",[24,127],"Spinal Cord Stimulation","2023-10-17",{"date":130,"type":31},"2023-10-18",{"date":132,"type":31},"2023-09-29",{"date":134,"type":20},"2026-09",{"name":113,"class":38},3]